Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.

Wolfsdorf JI, Ratner RE.

Diabetes Care. 2019 Jun;42(6):991-993. doi: 10.2337/dci19-0008. No abstract available.

PMID:
31110116
2.

Metformin and Type 2 Diabetes Prevention.

Aroda VR, Ratner RE.

Diabetes Spectr. 2018 Nov;31(4):336-342. doi: 10.2337/ds18-0020.

PMID:
30510389
3.

Hypoglycemia: New Definitions and Regulatory Implications.

Ratner RE.

Diabetes Technol Ther. 2018 Jun;20(S2):S250-S253. doi: 10.1089/dia.2018.0113. Epub 2018 Jun 6.

PMID:
29873525
4.

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M.

BMJ Open Diabetes Res Care. 2017 Oct 10;5(1):e000438. doi: 10.1136/bmjdrc-2017-000438. eCollection 2017. Erratum in: BMJ Open Diabetes Res Care. 2017 Oct 25;5(1):e000438corr1.

5.

Should We Screen for Type 2 Diabetes?

Petersen MP, Ratner RE.

Ann Intern Med. 2017 Apr 4;166(7):535. doi: 10.7326/L17-0027. No abstract available.

PMID:
28384739
6.

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.

Diabetes. 2017 Feb;66(2):241-255. doi: 10.2337/db16-0806. Epub 2016 Dec 15. Review.

7.

Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry.

Arnold SV, Inzucchi SE, McGuire DK, Mehta SN, Goyal A, Sperling LS, Maddox TM, Einhorn D, Wong ND, Ratner RE, Hammar N, Fenici P, Sheehan JJ, Wong JL, Kosiborod M.

Diabetes Care. 2016 Jul;39(7):e99-e101. doi: 10.2337/dc16-0585. Epub 2016 May 23. No abstract available.

PMID:
27222504
8.

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

J Clin Endocrinol Metab. 2016 May;101(5):2056-62. doi: 10.1210/jc.2015-4202. Epub 2016 Mar 16.

9.

American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome.

Semenkovich CF, Danska J, Darsow T, Dunne JL, Huttenhower C, Insel RA, McElvaine AT, Ratner RE, Shuldiner AR, Blaser MJ.

Diabetes. 2015 Dec;64(12):3967-77. doi: 10.2337/db15-0597. Epub 2015 Sep 29.

10.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

11.

The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome.

Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM.

J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. Review.

12.

Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium.

Leibel RL, Seeley RJ, Darsow T, Berg EG, Smith SR, Ratner R.

Diabetes. 2015 Jul;64(7):2299-309. doi: 10.2337/db15-0004. Review. No abstract available.

13.

Response to comment on Cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! Diabetes care 2014;37:3137-3138.

Cefalu WT, Petersen MP, Ratner RE.

Diabetes Care. 2015 May;38(5):e82-3. doi: 10.2337/dc15-0215. No abstract available.

14.

The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.

Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, Delahanty LM, Montez MG, Ackermann RT, Zhuo X, Knowler WC, Ratner RE; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2015 Apr;100(4):1646-53. doi: 10.1210/jc.2014-3761. Epub 2015 Feb 23.

15.

A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.

Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA.

J Clin Endocrinol Metab. 2015 May;100(5):1855-62. doi: 10.1210/jc.2014-3824. Epub 2015 Jan 20.

16.

Association of modifiable risk factors and left ventricular ejection fraction among hospitalized Native Hawaiians and Pacific Islanders with heart failure.

Mau MK, Seto TB, Kaholokula JK, Howard B, Ratner RE.

Hawaii J Med Public Health. 2014 Dec;73(12 Suppl 3):14-20.

17.

The alarming and rising costs of diabetes and prediabetes: a call for action!

Cefalu WT, Petersen MP, Ratner RE.

Diabetes Care. 2014 Dec;37(12):3137-8. doi: 10.2337/dc14-2329. No abstract available.

18.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME.

Am J Kidney Dis. 2014 Oct;64(4):510-33. doi: 10.1053/j.ajkd.2014.08.001.

PMID:
25257325
19.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME.

Diabetes Care. 2014 Oct;37(10):2864-83. doi: 10.2337/dc14-1296.

20.

We can change the natural history of type 2 diabetes.

Phillips LS, Ratner RE, Buse JB, Kahn SE.

Diabetes Care. 2014 Oct;37(10):2668-76. doi: 10.2337/dc14-0817.

21.

Communicating science-based recommendations with memorable and actionable guidelines.

Ratner RK, Riis J.

Proc Natl Acad Sci U S A. 2014 Sep 16;111 Suppl 4:13634-41. doi: 10.1073/pnas.1320649111. Epub 2014 Sep 15.

22.

A survey of genetic counselors about the needs of 18-25 year olds from families with hereditary breast and ovarian cancer syndrome.

Werner-Lin A, Ratner R, Hoskins LM, Lieber C.

J Genet Couns. 2015 Feb;24(1):78-87. doi: 10.1007/s10897-014-9739-y. Epub 2014 Jul 12.

PMID:
25011978
23.

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA; Harmony 6 Study Group.

Diabetes Care. 2014 Aug;37(8):2317-25. doi: 10.2337/dc14-0001. Epub 2014 Jun 4.

PMID:
24898300
24.

Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

Diabetes Care. 2014 Jun;37(6):1706-11. doi: 10.2337/dc13-1745. Epub 2014 Apr 4.

25.

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).

Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE.

J Diabetes Complications. 2014 May-Jun;28(3):386-92. doi: 10.1016/j.jdiacomp.2014.01.012. Epub 2014 Jan 28.

26.

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators.

Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31. doi: 10.1016/S2213-8587(13)70013-5. Epub 2013 Jul 9.

PMID:
24622318
27.

The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.

Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang Yu P, Ryden LE, Pirags V, Spinas GA, Birkeland KI, Ratner RE, Marin-Neto JA, Keltai M, Riddle MC, Bosch J, Yusuf S, Gerstein HC; ORIGIN Trial Investigators.

Diabetes Care. 2014;37(5):1360-6. doi: 10.2337/dc13-1468. Epub 2014 Feb 26.

PMID:
24574355
28.

A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative.

Shah BR, Cox M, Inzucchi SE, Foody JM, Zimmer LO, Jorge CB, Ratner RE, Barringer TA, McGuire DK, Peterson ED.

Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):400-7. doi: 10.1016/j.numecd.2013.09.010. Epub 2013 Nov 1.

PMID:
24374006
29.
30.

Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus.

Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, Kim C, Knowler WC, Christophi CA, Ratner R; Diabetes Prevention Program Research Group.

Diabetes Care. 2014 Apr;37(4):909-11. doi: 10.2337/dc13-0700. Epub 2013 Nov 22.

31.

Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; Diabetes Prevention Program Research Group.

Diabetes Obes Metab. 2014 Apr;16(4):326-33. doi: 10.1111/dom.12220. Epub 2013 Oct 29.

32.

Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study.

Diabetes Care. 2013 Nov;36(11):3607-12. doi: 10.2337/dc13-0520. Epub 2013 Sep 23.

33.

Kynurenines and vitamin B6: link between diabetes and depression.

Oxenkrug G, Ratner R, Summergrad P.

J Bioinform Diabetes. 2013 Sep 14;1(1). pii: http://openaccesspub.org/journals/download.php?file=51-OAP-JBD-IssuePDF.pdf.

34.

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.

Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R.

Diabetes Obes Metab. 2014 Feb;16(2):170-8. doi: 10.1111/dom.12192. Epub 2013 Aug 22.

PMID:
23911196
35.

Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study.

Diabetes. 2013 Nov;62(11):3920-6. doi: 10.2337/db13-0265. Epub 2013 Jul 17.

36.

Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes.

Hill JO, Galloway JM, Goley A, Marrero DG, Minners R, Montgomery B, Peterson GE, Ratner RE, Sanchez E, Aroda VR.

Diabetes Care. 2013 Aug;36(8):2430-9. doi: 10.2337/dc13-1161. Epub 2013 Jun 20. Review. No abstract available.

37.

[Food quality and nutritional status in university students of eleven Chilean regions].

Ratner RG, Hernández PJ, Martel JA, Atalah ES.

Rev Med Chil. 2012 Dec;140(12):1571-9. doi: 10.4067/S0034-98872012001200008. Spanish.

38.

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

Bray GA, Smith SR, Banerji MA, Tripathy D, Clement SC, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Schwenke DC, Stentz FB, Reaven PD, DeFronzo RA.

Diabetes Obes Metab. 2013 Oct;15(10):931-7. doi: 10.1111/dom.12099. Epub 2013 May 7.

PMID:
23551856
39.

Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.

Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB; Diabetes Prevention Program Research Group.

Am J Manag Care. 2013;19(3):194-202.

40.

Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes.

Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE.

Diabetes Technol Ther. 2013 Feb;15(2):117-23. doi: 10.1089/dia.2012.0211. Epub 2013 Jan 10.

41.
42.

N-acetylserotonin and aging-associated cognitive impairment and depression.

Oxenkrug G, Ratner R.

Aging Dis. 2012 Aug;3(4):330-8. Epub 2012 Jun 19.

43.

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD.

Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):393-9. doi: 10.1161/ATVBAHA.112.300346. Epub 2012 Nov 21. Erratum in: Arterioscler Thromb Vasc Biol. 2013 May;33(5):e114.

44.

The imperative to prevent diabetes.

Ratner RE.

Diabetes Care. 2012 Dec;35(12):2417-8. doi: 10.2337/dc12-1997. No abstract available.

45.

Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults.

Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E, Kahn SE; Diabetes Prevention Program Research Group.

J Diabetes Complications. 2013 Mar-Apr;27(2):150-7. doi: 10.1016/j.jdiacomp.2012.09.012. Epub 2012 Nov 7.

46.

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R; T-emerge 2 Study Group.

Diabetes Care. 2013 Mar;36(3):498-504. doi: 10.2337/dc12-0709. Epub 2012 Nov 8.

47.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B.

Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3.

48.

Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes.

Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ.

Diabetes Care. 2012 Nov;35(11):2331-6. doi: 10.2337/dc12-0053. Epub 2012 Jul 30.

49.

Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.

Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, Marcovina SM, Montez M, Ratner RE, Saudek CD, Sherif H, Watson KE.

Diabet Med. 2013 Jan;30(1):46-55. doi: 10.1111/j.1464-5491.2012.03750.x.

50.

The American Diabetes Association diabetes research perspective.

Fonseca VA, Kirkman MS, Darsow T, Ratner RE.

Diabetes Care. 2012 Jun;35(6):1380-7. doi: 10.2337/dc12-9001. No abstract available. Erratum in: Diabetes Care. 2012 Jul;35(7):1629.

Supplemental Content

Loading ...
Support Center